Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

Figure 1

CT-322 reduces tumor size in a xenograft model of pancreatic cancer. Human MiaPaCa-2 tumors were established in the tail of the pancreas in athymic nude mice. Therapy was initiated 10 days after tumor cell injection. Treatment with the anti-VEGFR2 Adnectin CT-322 (30 mg/kg) was given by i.p. injection twice weekly for 6 weeks (until sacrifice). Mean (+/- SEM) tumor weight at the time of sacrifice is displayed. CT-322 significantly reduced tumor size compared to control treated animals (Control 1.11 ± 0.17 g, CT-322 0.64 ± .010 g; n = 9 animals per group. *p < 0.05).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us